

# The UK-Irish Atopic Eczema Systemic Therapy Register

**First published:** 19/06/2024

**Last updated:** 06/05/2026

Data source

Human

Disease registry

## Administrative details

### Administrative details

**Data source ID**

1000000210

---

**Data source acronym**

A-STAR

---

**Data holder**

[King's College London](#)

---

**Data source type**

Disease registry

---

**Main financial support**

Funding from industry or contract research

Funds from patients organisations, charity and foundations

National, regional, or municipal public funding

---

### Care setting

Secondary care – specialist level (ambulatory)

---

### Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

---

### Data source website

[A-STAR website](#)

## Contact details

Carsten Flohr [carsten.flohr@kcl.ac.uk](mailto:carsten.flohr@kcl.ac.uk)

Main

[carsten.flohr@kcl.ac.uk](mailto:carsten.flohr@kcl.ac.uk)

Alan Irvine [IRVINEA@tcd.ie](mailto:IRVINEA@tcd.ie)

Alternate

[IRVINEA@tcd.ie](mailto:IRVINEA@tcd.ie)

## Data source regions and languages

### Data source countries

Ireland

United Kingdom

---

## Data source languages

English

---

## Data source regions

England

New Ireland

Northern Ireland

Scotland

Wales [Cymru GB-CYM]

## Data source establishment

### Data source established

30/07/2018

---

### Data source time span

**First collection:** 05/10/2018

The date when data started to be collected or extracted.

## Publications

### Data source publications

[Mapping exercise and status update of eight established registries within the Treatment of Atopic Eczema Registry Taskforce](#)

[Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types](#)

[A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register](#)

The UK-Irish Atopic eczema Systemic TherApy Register (A-STAR): baseline characteristics of the cohort

## Studies

### List of studies that have been conducted using the data source

A pan-European registry-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis (Dream to TREAT AD)

## Data elements collected

### The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

Yes

---

#### **Disease details**

Dermatitis atopic

---

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

---

## **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

---

## **Hospital admission and/or discharge**

Yes

---

## **ICU admission**

Is information on intensive care unit admission available?

Yes

---

## **Cause of death**

Captured

---

## **Cause of death vocabulary**

MedDRA

---

## **Prescriptions of medicines**

Captured

---

## **Prescriptions vocabulary**

other

---

## **Prescriptions vocabulary, other**

Names defined by the study protocol and the study group

---

## **Dispensing of medicines**

Not Captured

---

## **Advanced therapy medicinal products (ATMP)**

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

---

## **Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

---

## **Indication for use**

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

---

## **Indication vocabulary**

Not coded (Free text)

---

## **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

Yes

---

## **Administration of vaccines**

No

---

## **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

---

## **Procedures vocabulary**

Not coded (Free text)

---

### **Healthcare provider**

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available?  
The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

No

---

### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

---

### **Genetic data**

Are data related to genotyping, genome sequencing available?

Not Captured

---

### **Biomarker data**

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Not Captured

---

### **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

Yes

---

### **Patient-generated data**

Is patient-generated information (e.g., from wearable devices) available?

No

---

## **Units of healthcare utilisation**

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

---

## **Unique identifier for persons**

Are patients uniquely identified in the data source?

Yes

---

## **Diagnostic codes**

Captured

---

## **Diagnosis / medical event vocabulary**

ICD-10

---

## **Medicinal product information**

Captured

---

## **Medicinal product information collected**

Active ingredient(s)

Dosage regime

Dose

Route of administration

---

## **Medicinal product vocabulary**

Other

---

## **If 'other,' what vocabulary is used?**

Pre-defined names selected by the study group

---

## **Quality of life measurements**

Captured

---

## **Quality of life measurements vocabulary**

EQ5D

HRQOL

---

## **Lifestyle factors**

Not Captured

---

## **Sociodemographic information**

Captured

---

## **Sociodemographic information collected**

Age

Country of origin

Education level

Ethnicity

Sex

## Quantitative descriptors

## Population Qualitative Data

### **Population age groups**

All

Paediatric Population (< 18 years)

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adult and elderly population ( $\geq 18$  years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly ( $\geq 65$  years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

## Population

### **Population size**

1550

---

### **Active population size**

1250

## Median observation time

**Median time (years) between first and last available records for unique individuals captured in the data source**

2.00

## Data flows and management

## Access and validation

## **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

---

## **Access to subject details**

Can individual patients/practitioners/practices included in the data source be contacted?

No

---

## **Description of data collection**

Core dataset collected was developed within TREAT Registry Taskforce as a result of consensus exercise and implemented into A-STAR (<https://pubmed.ncbi.nlm.nih.gov/30719709/>). It includes patient demographics, past medical history, eczema treatment history, disease outcomes at baseline and at follow-up, as well as changes in the treatment and the healthcare resource use.

# Event triggering registration

## **Event triggering registration of a person in the data source**

Start of treatment

---

## **Event triggering de-registration of a person in the data source**

Death

Loss to follow up

---

## **Event triggering creation of a record in the data source**

Visit of the dermatology department when on systemic treatment for atopic eczema.

# Data source linkage

## **Linkage**

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

---

# Data management specifications that apply for the data source

## **Data source refresh**

Monthly

---

## **Informed consent for use of data for research**

Other

---

## **Possibility of data validation**

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

---

## **Data source preservation**

Are records preserved in the data source indefinitely?

Yes

---

## **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

Yes

---

## **Informed consent, other**

Already included into the original consent

---

## **Data source last refresh**

30/04/2026

# Common Data Model (CDM) mapping

## **CDM mapping**

Has the data source been converted (ETL-ed) to a common data model?

Yes

## **CDM Mappings**

### **CDM name**

OMOP

---

### **CDM website**

<https://www.ohdsi.org/Data-standardization/>

---

### **Data source ETL status**

Completed